Coronary Artery Dilatations and Aneursyms
Conditions
Brief summary
Objectives: The discovery of aneurysmal or ectatic lesions of the coronary arteries during coronary angiography or coronary CT angiography poses a triple challenge in terms of aetiology, treatment and prognosis. The aim of this study, based on coronary angiograms performed over a 10-year period at the Centre Hospitalier de Versailles, was to determine which antithrombotic treatment was routinely prescribed to patients with ACC or AEC, the evolution of this long-term treatment, and to analyse the association between the presence/absence of anticoagulant treatment and the rates of ischaemic cardiovascular events and haemorrhagic complications. Materials and methods: This is a non-interventional, observational, single-centre study conducted at the Versailles Hospital Centre from 2013 to 2023, based on the department's coronary angiography registry. The study included adult patients, living or deceased, hospitalised in the cardiology department who underwent coronary angiography between 1 January 2013 and 31 December 2023, which showed the presence of aneurysms or ectatic atheroma with bi- or tri-vessel coronary involvement.
Interventions
OTHERAnticoagulant Treatment
Follow-up of patients with coronary aneurysms and treatments introduced (anticoagulants and/or antiplatelet agents) to monitor the onset of ischaemic or haemorrhagic complications between 2013 and 2023.
Sponsors
Franck Assayag
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient \> 18 years old * Patient living or deceased * Patient with aneurysmal or ectatic coronary artery disease with bi- or tri-truncular involvement at coronary angiography.
Exclusion criteria
* Patient \< 18 years old * Monotruncal aneurysmal or ectatic disease * Absence of coronary aneurysm / ectasia * Patient's opposition to participation in research
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The nature of the antithrombotic treatment prescribed between the initial hospital discharge and the follow-up date | Treatment on discharge from hospital and follow-up treatment beween 2013 and 2023 | The nature of the antithrombotic treatment prescribed between the initial hospital discharge and the follow-up date (anti-platelet agents alone, single or dual therapy, anticoagulant alone, anti-platelet agent-anticoagulant combinations). |
| The nature of antithrombotic treatments | Discharge from hospital (day 1) | The nature of antithrombotic treatments |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The occurrence of ischaemic cardiovascular events (cardiovascular death, myocardial infarction, unscheduled coronary revascularisation) | The follow-up period between 2013 and 2023 | The occurrence of ischaemic cardiovascular events (cardiovascular death, myocardial infarction, unscheduled coronary revascularisation) |
| The occurrence of haemorrhagic events of any kind | The follow-up period between 2013 and 2025 | The occurrence of haemorrhagic events of any kind |
Countries
France
Outcome results
None listed